CARLSBAD, Calif.--(BUSINESS WIRE)--Sep. 23, 2019--
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, will be presenting at the 2019 Cell & Gene Meeting on the Mesa on October 3rd, 2019 at 5:00pm Pacific Time at the Park Hyatt Aviara Resort in the BlueRock Therapeutics Ballroom in Carlsbad, CA.
Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a premier conference combining discussions between senior executives and top decision-makers in the industry. The program also includes presentations by the field’s most promising companies in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies and extensive one-on-one partnering capabilities.
A live video webcast of all company presentations will be available at: http://www.meetingonthemesa.com/webcast and will also be published on the conference website shortly after the event.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical assets include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. Lineage is also evaluating potential partnership opportunities for Renevia®, a facial aesthetics product that was recently granted a Conformité Européenne (CE) Mark. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190923005243/en/
Source: Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
Solebury Trout IR
Gitanjali Jain Ogawa